Academic Curriculum Vitae of: **GREGORY PAPAGREGORIOU**, PhD

PERSONAL INFORMATION

Work Address: Molecular Medicine Research Center
The Medical School - SEKKY
University of Cyprus
215/6 Limassol Avenue
Floor -1
Strovolos
Nicosia
2029
Cyprus

Tel: +357-22-895259

Emails: papagregoriou@ucy.ac.cy

URLs:

- http://www.biobank.cy/
- http://www.linkedin.com/in/gregory-papagregoriou-b4533b29/
- http://www.researchgate.net/profile/Gregory_Papagregoriou
- http://scholar.google.com/citations?user=JJ74YX4AAAAJ&hl=en
- https://orcid.org/0000-0002-2440-9789

EDUCATION

May 2012	PhD in Molecular Biology Dept of Biological Sciences, University of Cyprus, Nicosia, Cyprus PhD Thesis: "microRNAs as genetic modifiers in inherited glomerulopathies" Supervisor: Prof. Constantinos Deltas
Aug 2006	MRes in Molecular and Medical Biosciences (Distinction) The Medical School, University of Newcastle, Newcastle-upon-Tyne, UK Thesis: ''Investigation of the genetic basis of L-Dopa-Responsive Dystonia'' Supervisor: Prof. Patrick F. Chinnery
Apr 2005	BSc in Biology, Department of Biology, Aristoteles University of Thessaloniki, Thessaloniki, Greece (GPA:7.34-HONS) Thesis: "Investigation of the neuroprotective or neurotoxic properties of glycose in the sensory neurons of the sciatic nerve in the frog *Rana ridibunda*, as a model for diabetic neuropathy." Supervisor: Prof. George Theophilides

EMPLOYMENT/APPOINTMENTS

Oct 2019-Present	Academic Board Member, biobank.cy Center of Excellence for Biobanking and Biomedical Research – Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus
Oct 2019-Present	Principal Investigator/Group Leader – Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus "Autosomal Dominant Tubulointerstitial Kidney Disease due to MUC1 mutations in Cyprus – Preparation of a clinical trial cohort, biomarker discovery and identification of new MUC1 mutations"
Jun 2017- Sep 2019	PostDoctoral Fellow (Co-Principal Investigator) – Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus "A Prospective Study of Patients with Mucin-1 Kidney Disease in Cyprus and Biomarker Discovery" PI: Prof. Constantinos Deltas
Feb 2017-Nov 2017	Scientist – Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA, and Brigham and Womens Hospital, Harvard Medical School, Harvard University, Boston, MA, USA "Biomarker discovery for MUC1 Kidney Disease – MKD" PI: Dr Anna Greka, MD, PhD
Feb-May 2014/16	Part-time lecturer – Department of Life and Health Sciences, University of Nicosia
Jun 2012-May 2017	Postdoctoral Fellow – Molecular Medicine Research Center, University of Cyprus, "microRNAs as regulators of gene expression by their direct binding on DNA target sequences" and "Genetic basis of familial hematuria" In charge of the Genetic Analysis Unit - Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus PI: Prof. Constantinos Deltas

GRANTS, SCHOLARSHIPS AND AWARDS

Ongoing:

Nov 2021 – Jun 2022: PI: Papagregoriou G & Deltas C., MMRC, University of Cyprus, Nicosia, CY

Role: Principal Investigator

Funding Body: Carlos Slim Center for Health Research at the Broad Institute of Harvard and MIT

Proposal: Clinical biomarkers for ADTKD-MUC1 as endpoints in prospective clinical trials (CY-BioMUC1) Amount: $105.000

Mar 2020 – Oct 2026: PI: Deltas C. – MMRC, University of Cyprus, Nicosia, CY

Role: Group Leader, MUC1 Kidney Disease

Funding Body/Call: European Union/SPREADING EXCELLENCE AND WIDENING PARTICIPATION/H2020-WIDESPREAD-01-2018-2019-Teaming Phase 2

Proposal: Biobanking and the Cyprus Human Genome Project (CY-Biobank), Amount: €30.000.000 (Year 1 – Year 7) + €8.000.000 (Year 8 – Year 15)

Dec 2019 – Jun 2022: PI: Constantinou A. – Dept of Biological Sciences, University of Cyprus, Nicosia, CY

Role: Collaborator – ctcDNA NGS

Funding Body/Call: Research and Innovation Foundation, Cyprus/EXCELLENCE HUBS - EXCELLENCE/0918/0313

Proposal: Investigation of the predictive and prognostic role of liquid biopsies in NSCLC patients treated with the anti- PD-1 inhibitor Pembrolizumab (PRELIFE), Amount: €249.996

Mar 2021 – Mar 2024: PI: Deltas C. – MMRC, University of Cyprus, Nicosia, CY

Role: WP Leader – Biomarker discovery, miRNAs in urinary extracellular vesicles

Funding Body/Call: Funding Body/Call: Research and Innovation Foundation, Cyprus/INTEGRATED/0918/0043

Proposal: Cyprus Genome Project and Nephrogenetics (CY-NEPHRON)

Amount: €1.000.000

Past:

Oct 2019 – Sep 2021: PI: Papagregoriou G – MMRC, University of Cyprus, Nicosia, CY

Role: Principal Investigator

Funding Body/Call: Research and Innovation Foundation, Cyprus/DIDAKTOR - POST-DOC/0718/0195

Proposal: Autosomal Dominant Tubulointerstitial Kidney Disease due to MUC1 mutations in Cyprus – Preparation of a clinical trial cohort, biomarker discovery and identification of new MUC1 mutations, Amount: €159.999

Oct 2019 – Oct 2021: PI: Deltas C., Co-PI: Papagregoriou G – MMRC, University of Cyprus, Nicosia, CY Co-PI: Stavrou C - Evangelismos Hospital, Pafos, CY.

Role: Co-Principal Investigator - Biobank Coordinator

Funding Body: Carlos Slim Center for Health Research at the Broad Institute of Harvard and MIT

Proposal: Open Label Study of the Effect of Cholecalciferol on Mucin-1 Levels in Individuals with Autosomal Dominant Tubulo-Interstitial Kidney Disease due to MUC1 Mutations (ADTKD-MUC1), Amount: $100.000

Dec 2018-Sep 2019: PI: Deltas C., Co-PI: Papagregoriou G – MMRC, University of Cyprus, Nicosia, CY Co-PI: Stavrou C - Evangelismos Hospital, Pafos, CY.

Role: Co-Principal Investigator

Funding Body: Carlos Slim Center for Health Research at the Broad Institute of Harvard and MIT

Proposal: A Prospective Study of Patients with Mucin-1 Kidney Disease in Cyprus and Biomarker Discovery (CY-MUC1) (Project SIGMA III) Amount: $148,401.96 University of Cyprus

Sep 2016-Aug 2019: PI: Prof. Loreto Gesualdo, University of Bari, Italy

Roles: Project Manager/Quality Controller for UCY/Lecturer.

Funding Body: European Commission Programme/Call: Erasmus+, KA2 - Cooperation for Innovation and the Exchange of Good Practices Strategic Partnerships for higher education

Proposal: Renal Molecular Pathologist network (ReMaP), Total budget: €390,632 Budget for UCY: €43,848

Jun 2017-Nov 2018: PI: Deltas C., Co-PI: Papagregoriou G – MMRC, University of Cyprus, Nicosia, CY Co-PI: Stavrou C - Evangelismos Hospital, Pafos, CY.

Role: Co-Principal Investigator

Funding Body: Carlos Slim Center for Health Research at the Broad Institute of Harvard and MIT

Proposal: A Prospective Study of Patients with Mucin-1 Kidney Disease in Cyprus and Biomarker Discovery (CY-MUC1) (Project SIGMA III) Amount: €198,990 University of Cyprus

Feb 2017-Nov 2017: PI: Dr Anna Greka, MD, PhD. Awarded a visiting scientist position, Broad Institute MIT and Harvard, MA, USA.
"Biomarker discovery for MUC1 Kidney Disease – MKD", Amount: $60,000

Oct 2007-May 2012: PhD Student Full Scholarship - Maria and George Tyrimos Foundation via the Pancyprian Gymnasium, Nicosia, Cyprus. Amount: €136.000

June 2012: Faculty of Pure and Applied Sciences award for academic and research performance for the PhD in Molecular Biology program, University of Cyprus, Nicosia, Cyprus

PROFESSIONAL BODIES/SOCIETIES

2007-Present: Cyprus Society of Human Genetics - CSHG

2020-Present: European Renal Association-European Dialysis and Transplant Association - ERA-EDTA

2016-Present: Cyprus Atherosclerosis Society - CAS (Founding Member)

2019-Present: European Atherosclerosis Society - EAS

2019-Present: βιοç-Society of Biological Sciences Cyprus - SBS (Founding Member)

2022-Present: International Society of Extracellular Vesicles- ISEV

TEACHING EXPERIENCE

Mar 2022: Lecture to postgraduate students, MEDMS705-Molecular Diagnostics, MSc in Precision Medicine in Clinical Practice, , Medical School, University of Cyprus, Nicosia, CY

Sep16-Aug19: Erasmus+/Renal Molecular Pathologist network (ReMaP) – Online recorded lectures on Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Tubulointerstitial Kidney Diseases, Next-Generation Sequencing using gene panels. On-site teaching and training of participating Pathology interns on molecular techniques.

Feb-May 2016: Lecturing for Molecular Biology Lab, Department of Life and Health Sciences, University of Nicosia

Feb-May 2014: Lecturing for Introduction to Biology I (Labs) and II (Lectures and labs), Department of Life and Health Sciences, University of Nicosia

Jan-May 2014:	Teaching assistant in Human Genetics, at the University of Cyprus (Instructor: Prof. Constantinos Deltas)
Jan-May 2013:	Teaching assistant in Human Genetics, at the University of Cyprus (Instructor: Prof. Constantinos Deltas)
Sep-Dec 2011:	Teaching assistant in Genetics, at the University of Cyprus (Instructor: Prof. Constantinos Deltas)
Sep-Dec 2010:	Teaching assistant in Genetics, at the University of Cyprus (Instructor: Prof. Constantinos Deltas)
Sep-Dec 2009:	Teaching assistant in Genetics laboratory exercises, at the University of Cyprus (Instructor: Prof. Constantinos Deltas)
Apr 2009:	Teaching trainer at the Pedagogic Institute of Cyprus for biology laboratory exercises.
Sep-Dec 2008:	Teaching assistant in Genetics laboratory exercises, at the University of Cyprus (Instructor: Prof. Constantinos Deltas)

WORKSHOPS/COURSES/PROFESSIONAL TRAINING

Jan 2020	GeneStudio S5 Plus and IonChef System Workflow Training Course for Next-Generation Sequencing in MMRC, UCY, Nicosia, CY
Jun 2015	Quantstudio 3D digital PCR Workflow Training Course in ThermoFisher Scientific Customer Experience Center, Paisley, Glasgow, UK
Nov 2013	Ion Torrent PGM System Workflow Training Course for Next-Generation Sequencing in Life Sciences Customer Experience Center, Paisley, Glasgow, UK
Aug 2012	FEBS Workshop in Non-Coding RNA in transcription, chromatin and epigenetics, Aarhus University, Denmark (Awarded a grant from the FEBS Young Travel Fund)
Sep 2010	COST Action: BM0702 Training School: "Matrix Assisted Laser Desorption Ionization Tissue Imaging (MALDI TI) of Kidney specimens on a high resolution mass spectrometer with Q-TOF Ion Mobility and TOF/TOF Imager Reference", Biomedicum, University of Helsinki, Finland (Awarded a traveling grant by the organizers)
Sep 2008	FEBS Advanced Practical Course in Gene Expression, Copy Number Variations in Genome, Single Cell Analysis: Arrays, Beads, Massive Parallel Sequencing, Prague, Czech Republic (Awarded a grant from the FEBS Young Travel Fund)

Feb 2007 Sequencing Analysis training on ABI PRISM 3130 in Applied Biosystems Headquarters, Warrington, UK

PUBLICATIONS IN PEER REVIEWED JOURNALS

1. Pieri M, Theori E, Dweep H, Flourentzou M, Kalampalika F, Maniori MA, **Papagregoriou G**, Papaneophytou C, Felekkis K (2022) A bovine miRNA, bta-miR-154c, withstands in vitro human digestion but does not affect cell viability of colorectal human cell lines after transfection. *FEBS Open Bio*;12(5):925-936 *(doi:10.1002/2211-5463.13402)*
2. Mamais I, Malatras A, **Papagregoriou G**, Giallourou N, Kakouri AC, Karayiannis P, Koliou M, Christaki E, Nikolopoulos GK, Deltas C (2021) Circulating IgG Levels in SARS-CoV-2 Convalescent Individuals in Cyprus. *J Clin Med;*10(24):5882 *(doi: 10.3390/jcm10245882)*
3. Antoniades A, Papaioannou MM, Malatras A, **Papagregoriou G**, Mueller H, Holub P, Deltas C, Schizas CN, (2021) Integration of Biobanks in National eHealth Ecosystems facilitating long term longitudinal clinical-omics studies, and citizen's engagement in research through eHealthBioR. *Frontiers in Digital Health*;3(57) *(doi:10.3389/fdgth.2021.628646)*
4. Odiatis C, Savva I, Pieri M, Ioannou P, Petrou P, **Papagregoriou G**, Antoniadou K, Makrides N, Stefanou H, Galešić Ljubanović D, Nikolaou G, Borza DB, Stylianou K, Gross O, Deltas C, (2021) A glycine substitution in the collagenous domain of Col4a3 in mice recapitulates late onset Alport syndrome. *Matrix Biology Plus*;9(10053) *(doi: 10.1016/j.mbplus.2020.100053)*
5. Živná M, Kidd K, Zaidan M, Vyleťal P, Barešová V, Hodaňová K, Sovová J, Hartmannová H, Votruba M, Trešlová H, Jedličková I, Sikora J, Hůlková H, Robins V, Hnízda A, Živný J, **Papagregoriou G**, Mesnard L, Beck BB, Wenzel A, Tory K, Häeffner K, Wolf MTF, Bleyer ME, Sayer JA, Ong ACM, Balogh L, Jakubowska A, Łaszkiewicz A, Clissold R, Shaw-Smith C, Munshi R, Haws RM, Izzi C, Capelli I, Santostefano M, Graziano C, Scolari F, Sussman A, Trachtman H, Decramer S, Matignon M, Grimbert P, Shoemaker LR, Stavrou C, Abdelwahed M, Belghith N, Sinclair M, Claes K, Kopel T, Moe S, Deltas C, Knebelmann B, Rampoldi L, Kmoch S, Bleyer AJ, (2020) An International Cohort Study of Autosomal Dominant Tubulointerstitial Kidney Disease due to REN Mutations Identifies Distinct Clinical Subtypes. *Kidney Int*; 98(6)1589-1604 *(doi:10.1016/j.kint.2020.06.041)*
6. Olinger E, Hofmann P, Kidd K, Dufour I, Belge H, Schaeffer C, Kipp A, Bonny O, Deltas C, Demoulin N, Fehr T, Fuster D, Gale D, Goffin E, Hodanova K, Hyunh-Do U, Kistler A, Morelle J, **Papagregoriou G**, Pirson Y, Sandford R, Sayer J, Torra R, Venzin C, Venzin R, Vogt B, Živná M, Greka A, Dahan K,

Rampoldi L, Kmoch S, Bleyer A Sr., Devuyst O. (2020) Clinical and Genetic Spectra of Autosomal Dominant Tubulointerstitial Kidney Disease due to Mutations in UMOD and MUC1. *Kidney Int*; 98(3):717-731 *(doi:10.1016/j.kint.2020.04.038)*

7. Christofides A[*], **Papagregoriou G**[*§], Dweep H, Makrides N, Gretz N, Felekkis K, Deltas C[§]. (2020) Evidence for miR-548c-5p regulation of FOXC2 transcription through a distal genomic target site in human podocytes. *Cell Mol Life Sci;* 77**,** 2441–2459 *(doi:10.1007/s00018-019-03294-z) [*]Authors with equal contribution, [§]Corresponding authors.*

8. Dvela-Levitt M, Kost-Alimova M, Emani M, Kohnert E, Thompson R, Sidhom EH, Rivadeneira A, Sahakian N, Roignot J, **Papagregoriou G**, Montesinos MS, Clark AR, McKinney D, Gutierrez J, Roth M, Ronco L, Elonga E, Carter TA, Gnirke A, Melanson M, Hartland K, Wieder N, Hsu JC, Deltas C, Hughey R, Bleyer AJ, Kmoch S, Živná M, Barešova V, Kota S, Schlondorff J, Heiman M, Alper SL, Wagner F, Weins A, Golub TR, Lander ES, Greka A. (2019) Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy. *Cell;* Jul 25, 178(3):521-535.e23 *(doi: 10.1016/j.cell.2019.07.002)*

9. Nwankwo EC, Mortega KG, Karageorgos A, Ogolowa BO, **Papagregoriou G**, Grether GF, Monadjem A, Kirschel ANG. (2019) Rampant introgressive hybridization in Pogoniulus tinkerbirds (Piciformes: Lybiidae) despite millions of years of divergence. *Biol J Linn Soc*;127(1)125-142 *(doi.org/10.1093/ biolinnean/blz018)*

10. Pitsios P, Iliopoulou A, Kontogianni M, **Papagregoriou G**. (2019) Detection of profiling in SPT extracts that are supposed to contain it. *Allergol Immunopathol (Madr)*;47(1)12-15 *(doi: doi.org/10.1016/j.aller.2018.05.003)*

11. Živná M, Kidd K, Přistoupilová A, Barešová V, DeFelice M, Blumenstiel B, Harden M, Conlon P, Lavin P, Connaughton DM, Hartmannová H, Hodaňová K, Stránecký V, Vrbacká A, Vyleťal P, Živný J, Votruba M, Sovová J, Hůlková H, Robins V, Perry R, Wenzel A, Beck BB, Seeman T, Viklický O, Rajnochová-Bloudíčková S, **Papagregoriou G**, Deltas CC, Alper SL, Greka A, Bleyer AJ, Kmoch S. (2018) Noninvasive Immunohistochemical Diagnosis and Novel MUC1 Mutations Causing Autosomal Dominant Tubulointerstitial Kidney Disease. *JASN*; 29(9):2418-2431 *(doi: 10.1681/ASN.2018020180)*

12. Voskarides K, **Papagregoriou G**, Hadjipanagi D, Petrou I, Savva I, Elia A, Athanasiou Y, Pastelli A, Kkolou M, Hadjigavriel M, Stavrou C, Pierides A, Deltas C. (2018) COL4A5 and LAMA5 variants co-

inherited in familial hematuria: digenic inheritance or genetic modifier effect? *BMC Nephrol*; 19:114 *(doi: 10.1186/s12882-018-0906-5)*

13. Kalogerou M, Kolovos P, Prokopiou E, **Papagregoriou G**, Deltas C, Malas S, Georgiou T. (2018) Omega-3 fatty acids protect retinal neurons in the DBA/2J hereditary glaucoma mouse model. *Exp Eye Res*;167:128-39 *(doi: 10.1016/j.exer.2017.12.005)*
14. Nagara M, **Papagregoriou G**, Ben Abdallah R, Landoulsi Z, Bouyacoub Y, Elouej S, Kefi R, Pippucci T, Voskarides K, Bashamboo A, McElreavey K, Hachicha M, Romeo G, Seri M, Deltas C, Abdelhak S. (2017) Distal renal tubular acidosis in a Libyan patient: Evidence of digenic inheritance. *Eur J Med Genet; pii: S1769-7212(16)30259-2. (doi: 10.1016/j.ejmg.2017.10.002.)*
15. Papazachariou L[*], **Papagregoriou G**[*], Hadjipanagi D, Demosthenous P, Voskarides K, Koutsofti C, Stylianou K, Ioannou P, Xydakis D, Tzanakis I, Papadaki A, Kallivretakis N, Nikolakakis N, Perysinaki G, Gale DP, Diamantopoulos A, Goudas P, Goumenos D, Soloukides A, Boletis I, Melexopoulou C, Georgaki E, Frysira E, Komianou F, Grekas D, Paliouras C, Alivanis P, Vergoulas G, Pierides A, Daphnis E, Deltas C. (2017) Frequent COL4 mutations in familial microhematuria accompanied by later-onset Alport nephropathy due to focal segmental glomerulosclerosis. *Clin Genet; Nov;92(5):517-527 (doi: 10.1111/cge.13077). *Authors with equal contribution*
16. Prokopiou E, Kolovos P, Kalogerou M, Neokleous A, **Papagregoriou G**, Deltas C, Malas S, Georgiou T. (2017) Therapeutic potential of omega-3 fatty acids supplementation in a mouse model of dry macular degeneration. *BMJ Open Ophth;1:e000056. (doi:10.1136/bmjophth-2016-000056)*
17. Koufaris C, **Papagregoriou G**, Kousoulidou L, Moutafi M, Tauber M, Jouret B, Kieffer I, Deltas C, Tanteles GA, Anastasiadou V, Patsalis PC, Sismani C. (2015) Haploinsufficiency of the miR-873/miR-876 microRNA cluster is associated with craniofacial abnormalities. *Gene* Apr 25;561(1):95-100 *(doi: 10.1016/j.gene.2015.02.018)*
18. Nagara M, Voskarides K, Elouej S, Zaravinos A, Riahi Z, **Papagregoriou G**, Kefi R, Boussetta K, Deltas C, Abdelhak S, Tinsa F. (2014) A novel splice-site mutation in ATP6V0A4 gene in two brothers with distal renal tubular acidosis from a consanguineous Tunisian family. *J Genet* Dec;93(3):859-6
19. Papazachariou L, Demosthenous P, Pieri M, **Papagregoriou G**, Savva I, Stavrou C, Zavros M, Athanasiou Y, Ioannou K, Patsias C, Panagides A, Potamitis C, Demetriou K, Prikis M, Hadjigavriel M, Kkolou M, Loukaidou P, Pastelli A, Michael A, Lazarou A, Arsali M, Damianou L, Goutziamani I, Soloukides A, Yioukas L, Elia A, Zouvani I, Polycarpou P, Pierides A, Voskarides K, Deltas C. (2014) Frequency of COL4A3/COL4A4 mutations amongst families segregating glomerular microscopic

hematuria and evidence for activation of the unfolded protein response. Focal and segmental glomerulosclerosis is a frequent development during ageing. *PLoS One*. Dec 16;9(12):e115015 *(doi: 10.1371/journal.pone.0115015)*

20. Zaravinos A, Lambrou GI, Mourmouras N, Katafygiotis P, **Papagregoriou G**, Giannikou K, Delakas D, Deltas C (2014) New miRNA Profiles Accurately Distinguish Renal Cell Carcinomas and Upper Tract Urothelial Carcinomas from the Normal Kidney. *PLoS One* 9(3):e91646 (doi: 10.1371/journal.pone.0091646)

21. Soloukides AP, Moutzouris DA, **Papagregoriou GN**, Stavrou CV, Deltas CC, Tzanatos HA, (2013) Renal graft outcome in autosomal dominant medullary cystic kidney disease type 1. *J Nephrol* Jul-Aug;26(4):793-8 *(doi: 10.5301/jn.5000249)*

22. **Papagregoriou G**, Dweep H, Voskarides K, Koupepidou P, Athanasiou Y, Pierides A, Gretz N, Felekkis KN, Deltas C, (2012) A miR-1207-5p Binding Site Polymorphism Abolishes Regulation of HBEGF and Is Associated with Disease Severity in CFHR5 Nephropathy. *PLoS One* 7(2):e31021 *(doi: 10.1371/journal.pone.0031021)*

23. Deltas C, **Papagregoriou G** (2010) Cystic Diseases of the Kidney: Molecular Biology and Genetics. *Arch Pathol Lab Med* 134(4):569-582. *(doi: 10.1043/1543-2165-134.4.569)*

24. Voskarides K, Makariou C, **Papagregoriou G**, Stergiou N, Printza N, Alexopoulos A, Elia A, Papachristou F, Pierides A, Georgaki E, Deltas C (2008) *NPHS2* screening with SURVEYOR in Hellenic children with steroid resistant nephrotic syndrome. *Pediatr Nephrol* 23(8):1373-1375. *(doi: 10.1007/s00467-008-0804-3)*

CHAPTER CONTRIBUTIONS

1. **Papagregoriou G** (2015) MicroRNAs in disease, In Felekkis KN & Voskarides K (Ed) *Genomic Elements in Health, Disease and Evolution: Junk DNA* (pp.17-46). DOI: 10.1007/978-1-4939-3070-8_2, Springer Publishing Group, New York, USA

INVITED REVIEWER

Biochemistry and Cell Biology, BMC Medical Genetics, Molecular Genetics & Genomic Medicine, Heliyon, Clinical Nephrology

SELECTED POSTER PRESENTATIONS IN INTERNATIONAL CONFERENCES

1. **Papagregoriou G**, Christofides A, Dweep H, Gretz N, Felekkis KN, Deltas C. (2014) The potential role of miR-548c-5p as a regulator of FOXC2 transcription to control podocyte differentiation, *Elsevier Cell Symposia: Regulatory RNAs*, Berkeley, CA, USA, Oct 19-21, 2014
2. **Papagregoriou G**, Christofides A, Dweep H, Gretz N, Felekkis KN, Deltas C. (2012) MicroRNAs are potential regulators of gene transcription by their direct binding on intergenic DNA target sequences in human cells: the hsa-miR-548c-5p example, *FEBS Workshop on Non-Coding RNA in Transcription, Chromatin and Epigenetics*, Aarhus, Denmark, Aug 6-10, 2012
3. **Papagregoriou G**, Dweep H, Voskarides K, Koupepidou P, Athanasiou Y, Pierides A, Gretz N, Felekkis KN, Deltas C. (2011) A DNA variant within the 3'-UTR of HBEGF alters the regulatory action of hsa-miR-1207-5p and is associated with progression of renal failure in CFHR5 nephropathy. *European Human Genetics Conference 2011,* Amsterdam, The Netherlands, May 28-31, 2011.
4. Tsiakkis D, Koupepidou P, Christodoulakis M, Pieri M, Felekkis KN, **Papagregoriou G**, Demosthenous P, Deltas C. (2011) Genotype-phenotype correlation in X-Linked Alport syndrome patients carrying missense mutations in the collagenous domain of COL4A5. *European Human Genetics Conference 2011,* Amsterdam, The Netherlands, May 28-31, 2011.
5. Felekkis KN, Sticht C, **Papagregoriou G**, Kranzlin B, Gretz N, Deltas C. (2010) The role of microRNAs (miRNA) in the development of Polycystic Kidney Disease. *5th International MicroRNAs Europe 2010 Meeting. MicroRNAs: Biology to Development and Disease*. University of Cambridge, Cambridge, UK. November 1-2, 2010.
6. **Papagregoriou G**, Dweep H, Voskarides K, Koupepidou P, Athanasiou Y, Pierides A, Gretz N, Felekkis KN, Deltas C, (2010) A miR-1207-5p binding site polymorphism in *HBEGF* gene is associated with disease severity in CFHR5 nephropathy *5th International MicroRNAs Europe 2010 Meeting. MicroRNAs: Biology to Development and Disease*. University of Cambridge, Cambridge, UK. November 1-2, 2010.
7. Felekkis KN, Sticht C, **Papagregoriou G**, Kranzlin B, Gretz N, Deltas C. (2010) The role of microRNAs (miRNA) in the development of Polycystic Kidney Disease. *5th Combined Management Committee and Working Groups Meeting of the COST Action BM0702 EuroKUP, on Kidney and Urine Proteomics*. Pissouri, Cyprus, November 6-7, 2010.
8. Pieri M, Felekkis KN, **Papagregoriou G**, Deltas C. (2010) Functional study of molecular pathomechanisms underlying glomerular basement membrane pathology *in vivo* and *in vitro*. *5th*

Combined Management Committee and Working Groups Meeting of the COST Action BM0702 EuroKUP, on Kidney and Urine Proteomics. Pissouri, Cyprus, November 6-7, 2010.

9. **Papagregoriou G**, Felekkis KN, Dweep H, Gretz N, Deltas C. (2009) MirSNPs as a contributing genetic factor to the variability of phenotypic severity recorded in congenital glomerulonephropathies. *MicroRNAs Europe 2009 Meeting. MicroRNAs: Biology to Development and Disease*. University of Cambridge, UK, November 2-3, 2009.
10. **Papagregoriou G**, Soloukides A, Voskarides K, Charalambous C, Pierides A, Hildebrandt F, Stavrou C, Deltas C. (2008) Medullary Cystic Kidney Disease 1 – The quest for finding the gene. *1st International Conference of Human Genetics*, organised by the Cyprus Society of Human Genetics. Nicosia, Cyprus, October 3-4, 2008.
11. Voskarides K, Makariou C, **Papagregoriou G**, Stergiou N, Printza N, Alexopoulos E, Elia A, Papachristou F, Pierides A, Georgaki E, Deltas C. (2008) SURVEYOR™ nuclease as a powerful mutation detection method: the example of *NPHS2* (podocin) screening in children from Greece and Cyprus with steroid-resistant nephrotic syndrome. *1st International Conference of Human Genetics*, organised by the Cyprus Society of Human Genetics. Nicosia, Cyprus, October 3-4, 2008.
12. Voskarides K, Makariou C, **Papagregoriou G**, Stergiou N, Printza N, Alexopoulos A, Elia A, Papachristou F, Pierides A, Georgaki E, Deltas C. (2008) *NPHS2* recurrent and novel mutations in children from Greece and Cyprus with steroid-resistant nephrotic syndrome**.** *European Human Genetics Conference 2008.* Barcelona, Spain, May 31-June 3, 2008.
13. **Papagregoriou G**, Soloukides A, Voskarides K, Charalambous C, Pierides A, Hildebrandt F, Stavrou C, Deltas C. (2008) Medullary Cystic Kidney Disease 1 – The quest for finding the gene. *European Human Genetics Conference 2008.* Barcelona, Spain, May 31-June 3, 2008

ORAL PRESENTATIONS/INVITED LECTURES/SEMINARS/TALKS

1. **Papagregoriou G**. From registries to clinical trials: How biobanking of rare diseases can unlock drug development paths, 16 May 2022, Invited talk, MediEuro Network Workshop, biobank.cy, University of Cyprus, Nicosia, Cyprus
2. **Papagregoriou G. "**MUC1 Makes Me Miserable", 17 Mar 2022, Invited plenary talk by the Cyprus Society of Human Genetics, Nicosia, Cyprus

3. **Papagregoriou G.** biobank.cy – Profile and Research Activities, 11th Mar 2022, Invited talk, Familial Hypercholesterolemia Meeting, Limassol General Hospital, Limassol, Cyprus.
4. **Papagregoriou G.** & Roignot J., Developing Biomarkers for ADKTD-*MUC1*, 19 Nov 2021, Invited plenary talk, 2nd International ADTKD Summit (Virtual)
5. **Papagregoriou G.,** Stavrou C., Christofides A., Zivna M., Roignot J., Kidd K., Kmoch S., Bleyer AJ., Greka A., Deltas C. Following Autosomal Dominant Tubulointerstitial Kidney Disease due to MUC1 mutations in Cyprus – Molecular analysis, deep phenotyping, and research to identify effective therapeutics, 13 May – 16 May 2021 (Virtual), Selected abstract for oral presentation, 22nd Conference of the Greek Society of Nephrology.
6. **Papagregoriou G.,** Stavrou C., Christofides A., Roignot J., Kuhn E., Zivna M., Kidd K., Kmoch S., Bleyer AJ., Greka A., Deltas C. Biobanking of rare kidney diseases and clinical trials: The example of ADTKD-MUC1 in Cyprus, 12 Nov – 21 Nov 2020 (On-Demand Session), Selected abstract for oral presentation, Europe Biobank Week 2020, Virtual Conference.
7. **Papagregoriou G.** ADTKD in Cyprus, 24 Sep 2020, Invited talk, 1st Annual ADTKD Virtual International Summit.
8. **Papagregoriou G.** From Biobanking to a clinical trial – the case for *MUC1* kidney disease, 10 Dec 2019, Meeting of the Biobanking Research Infrastructures of Austria, Italy, Cyprus & Czech Republic, Graz, Austria
9. **Papagregoriou G.** ADTKD-*MUC1* in the Cypriot population: Genotyping, deep-phenotyping, biomarker discovery and the search for a robust treatment, 14 Jun 2019, Selected abstract for oral presentation (FO067), 56th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Conference, Budapest, Hungary
10. **Papagregoriou G.** ADTKD-*MUC1* in the Cypriot population: Genotyping, deep-phenotyping, biomarker discovery and the search for a robust treatment, 8 Dec 2018, Oral Presentation, 7th International Conference of the Cyprus Society of Human Genetics, Nicosia, Cyprus
11. **Papagregoriou G.** *MUC1* Kidney Disease in Cyprus – Genetics, diagnostics and therapeutics, 21 Nov 2018, Invited Lecture, Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus
12. **Papagregoriou G.** Pharmacogenomics and the role of microRNAs, 04 Nov 2017, Invited Lecture, 20th Golden Helix Pharmacogenomics Day, Medical School, University of Cyprus, Nicosia, Cyprus

13. **Papagregoriou G.** The potential role of mir-548c-5p as a regulator of FOXC2 transcription to control podocyte differentiation. 21-24 Apr 2016, Oral Presentation, 28th European Renal Cell Study Group meeting, Paris, France
14. **Papagregoriou G.** Deciphering the genetic basis of familial hematuria by next-generation sequencing, 25 Feb 2015, Invited Seminar, Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus